Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial [Yahoo! Finance]
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors [Seeking Alpha]
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Sutro Biopharma, Inc. (NASDAQ: STRO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $11.00 price target on the stock, down previously from $12.00.